|
TRERF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.08797473439427E-13 |
| Normal-vs-Stage2 |
4.33759999995953E-06 |
| Normal-vs-Stage3 |
4.142131082574E-12 |
| Normal-vs-Stage4 |
7.19946324778675E-12 |
| Stage1-vs-Stage2 |
3.638600E-01 |
| Stage1-vs-Stage3 |
6.533800E-02 |
| Stage1-vs-Stage4 |
5.188100E-02 |
| Stage2-vs-Stage3 |
3.566000E-02 |
| Stage2-vs-Stage4 |
3.803800E-02 |
| Stage3-vs-Stage4 |
7.051800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
1.403710E-04 |
| Normal-vs-Asian |
1.46130000322486E-08 |
| Caucasian-vs-AfricanAmerican |
2.925200E-01 |
| Caucasian-vs-Asian |
5.827400E-01 |
| AfricanAmerican-vs-Asian |
5.483000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.25170004863884E-09 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.101390E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.87501142284918E-12 |
| Normal-vs-Age(41-60Yrs) |
1.79856129989275E-14 |
| Normal-vs-Age(61-80Yrs) |
5.24949994584745E-09 |
| Normal-vs-Age(81-100Yrs) |
3.117100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.309400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.830200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.483800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.624600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.539200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.377200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.296400E-02 |
| Classical-VS-Follicular |
1.865650E-02 |
| Classical-VS-Other |
6.133000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.676050E-03 |
| Tall-VS-Other |
6.464200E-01 |
| Tall-VS-Normal |
6.42749964363531E-10 |
| Follicular-VS-Other |
2.611600E-01 |
| Follicular-VS-Normal |
2.09939999999964E-05 |
| Other-VS-Normal |
9.428400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.95543581327229E-12 |
| Normal-vs-N1 |
1.72184488889116E-12 |
| N0-vs-N1 |
1.401530E-03 |
|
|
